Last reviewed · How we verify
NCT06681259
Clinical Specialty Queue For Gestational Trophoblastic Neoplasia
trial in Gestational Trophoblastic Neoplasia in 1,000 participants. Currently enrolling.
4 November 2029
Quick facts
| Lead sponsor | Women's Hospital School Of Medicine Zhejiang University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 4 November 2024 |
| Primary completion | 4 November 2029 |
| Estimated completion | 4 November 2029 |
| Sites | 1 location across China |
Conditions studied
- Gestational Trophoblastic Neoplasia — all drugs for Gestational Trophoblastic Neoplasia →
Sponsor
Women's Hospital School Of Medicine Zhejiang University
Who can join
18 and older, female only, with Gestational Trophoblastic Neoplasia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to establish a bidirectional cohort study of GTN specific diseases, including 1020 retrospective cases Queue and 1000 prospective cohorts. Based on the clinical collaboration system for gynecological tumors in multiple tertiary hospitals across the country, establish unified criteria for case inclusion and exclusion, and establish a multi center clinical queue for GTN; Collect baseline information of GTN patients, such as age, reproductive history, environmental and social information, genetic related information, physical examination, physicochemical, imaging, and pathological information; Collect biological specimens such as blood/tissue from patients; Collect information related to the diagnosis, treatment plan, human chorionic gonadotropin (hCG) levels, and toxic side effects of patients during the diagnosis and treatment period; After the end of treatment, follow-up blood hCG levels, imaging, fertility status, as well as recurrence and metastasis status, are conducted to track prognosis, thus building a clinical diagnosis and treatment information database, forming a standardized follow-up system for GTN, identifying high-risk factors for GTN chemotherapy resistance, constructing a precise evaluation model for GTN resistance, and providing high-level evidence-based medicine for effectively improving the initial treatment efficacy of GTN.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06681259
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gestational Trophoblastic Neoplasia
Currently open trials in the same condition.
- NCT06169644 — The Psychological Impact of GTN on Women Who Have Completed Chemotherapy Treatment · recruiting
- NCT05635344 — A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic Neoplasi · Phase 2 · recruiting
- NCT05139095 — Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia · Phase 2 · recruiting
- NCT03785574 — Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung Nodule · NA · recruiting
Other Women's Hospital School Of Medicine Zhejiang University trials
Trials by the same sponsor.
- NCT07369986 — Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer · Phase 2 · not yet recruiting
- NCT07244965 — Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervica · Phase 2 · not yet recruiting
- NCT06561308 — Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer · Phase 2 · recruiting
- NCT07106853 — Prenatal Cell-free DNA Screening in Pregnancies With Diverse Genetic Risk Profiles Utilizing Targeted and Whole-exome Se · not yet recruiting
- NCT07082530 — A RCT of Labor Induction at 39 Weeks in Low - Risk Women in China · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06681259 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Women's Hospital School Of Medicine Zhejiang University
- Last refreshed: 12 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06681259.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing